Technology Feasibility Assessment for Viral Nervous Necrosis Prevention and Management

A leading biotechnology firm engaged Stellarix for competitive benchmarking and technology feasibility assessment. Our strategic insights helped the client accelerate market readiness by identifying gaps and pinpointing scalable innovations in aquaculture, specifically supporting the development of commercial vaccines for VNN (Viral Nervous Necrosis).

Client Background:

A Global life sciences and biotechnology conglomerate specializing in sustainable aquaculture health, marine biosecurity, and advanced animal health therapeutics. The enterprise is highly invested in innovation-driven biotechnology, secondary bacterial co-infections, and emerging marine pathogens.

Engagement Objective:

The objective of the search was to conduct a technical due diligence evaluation of ‘Sundew ApS’. The focus would be to assess technological feasibility relative to similar companies in the field. The resulting solutions preferably would address three requirements – ease of fish vaccination, ROI for investors, and sustainability (climate-friendly). Technological advancements have had a considerable impact on mass vaccination and the development of edible oral vaccines, enabling the commercial production of a VNN vaccine.

Client Impact:

• Competitive benchmarking and evidence-based assessment of Sundew’s vaccine platform helped identify innovations (e.g., oral delivery, edible vaccines, mass-administration routes) that are technically scalable and manufacturable.
• Identified gaps where Sundew ApS can collaborate (formulation partners, fish-health majors, feed companies) to accelerate market readiness.
• Insights on how Sundew’s platform could enable commercial vaccines for VNN (Viral Nervous Necrosis) in a high-burden unmet need in aquaculture.

Outcome Snapshot: